Skip to main navigation Skip to search Skip to main content

Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications

  • Kenneth W. Witwer
  • , Bas W.M. Van Balkom
  • , Stefania Bruno
  • , Andre Choo
  • , Massimo Dominici
  • , Mario Gimona
  • , Andrew F. Hill
  • , Dominique De Kleijn
  • , Mickey Koh
  • , Ruenn Chai Lai
  • , S. Alex Mitsialis
  • , Luis A. Ortiz
  • , Eva Rohde
  • , Takashi Asada
  • , Wei Seong Toh
  • , Daniel J. Weiss
  • , Lei Zheng
  • , Bernd Giebel
  • , Sai Kiang Lim*
  • *Corresponding author for this work
  • Johns Hopkins University
  • International Society for Extracellular Vesicles (ISEV)
  • University Medical Center Utrecht
  • University of Turin
  • Agency for Science, Technology and Research, Singapore
  • Society for Clinical Research and Translation of Extracellular Vesicles Singapore (SOCRATES)
  • MAB Laboratory
  • University of Modena and Reggio Emilia
  • International Society for Cell and Gene Therapy (ISCT)
  • Paracelsus Private Medical University
  • La Trobe University
  • St George’s University Hospitals NHS Foundation Trust
  • Health Sciences Authority, Government of Singapore
  • International Society of Blood Transfusion (ISBT)
  • Boston Children's Hospital
  • University of Pittsburgh
  • Kyoto University
  • National University of Singapore
  • University of Vermont
  • Southern Medical University
  • University of Duisburg-Essen

Research output: Contribution to journalArticlepeer-review

569 Scopus citations

Abstract

Small extracellular vesicles (sEVs) from mesenchymal stromal/stem cells (MSCs) are transiting rapidly towards clinical applications. However, discrepancies and controversies about the biology, functions, and potency of MSC-sEVs have arisen due to several factors: the diversity of MSCs and their preparation; various methods of sEV production and separation; a lack of standardized quality assurance assays; and limited reproducibility of in vitro and in vivo functional assays. To address these issues, members of four societies (SOCRATES, ISEV, ISCT and ISBT) propose specific harmonization criteria for MSC-sEVs to facilitate data sharing and comparison, which should help to advance the field towards clinical applications. Specifically, MSC-sEVs should be defined by quantifiable metrics to identify the cellular origin of the sEVs in a preparation, presence of lipid-membrane vesicles, and the degree of physical and biochemical integrity of the vesicles. For practical purposes, new MSC-sEV preparations might also be measured against a well-characterized MSC-sEV biological reference. The ultimate goal of developing these metrics is to map aspects of MSC-sEV biology and therapeutic potency onto quantifiable features of each preparation.

Original languageEnglish
Article number1609206
JournalJournal of Extracellular Vesicles
Volume8
Issue number1
DOIs
StatePublished - 1 Jan 2019
Externally publishedYes

Keywords

  • Definition
  • MSC
  • Please check whether the inserted Keywords are correct
  • Therapeutics
  • sEV

Fingerprint

Dive into the research topics of 'Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications'. Together they form a unique fingerprint.

Cite this